RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort. (2023)

First Author: O'Sullivan JM
Attributed to:  Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41375-023-02027-3

PubMed Identifier: 37864122

Publication URI: http://europepmc.org/abstract/MED/37864122

Type: Journal Article/Review

Volume: 37

Parent Publication: Leukemia

Issue: 12

ISSN: 0887-6924